Latest news with #Adela
Yahoo
30-05-2025
- Business
- Yahoo
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting
FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is presenting results of two studies demonstrating the ability of its MRD test to predict progression and identify non-responders to immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 – June 3, 2025. "In patients with advanced cancer receiving immunotherapy, it can be challenging to differentiate true progression from pseudoprogression during early treatment cycles based on imaging," said Lillian Siu, MD, FRCPC, Medical Oncologist and Senior Scientist, Princess Margaret Cancer Centre, University Health Network. "To better identify non-responders and guide timely treatment adjustments, more reliable response assessment tools are needed. Methylation-based circulating tumor DNA (ctDNA) technology shows promise in these regards." The ability of Adela's test to identify progression in patients treated with immunotherapy was demonstrated in two studies. The first study included banked samples from 64 patients with advanced head & neck, breast, ovarian, melanoma, or other solid tumors who received pembrolizumab. Blood samples were collected pre-treatment and prior to initiation of cycle 3 of treatment. A decrease in ctDNA from the pre-treatment blood draw to the pre-cycle 3 blood draw was associated with a significantly better PFS [hazard ratio (HR) of 0.28 (0.15, 0.49); p<0.0001] and OS [HR 0.42 (0.24, 0.76); p=0.003]. "These results show promise in assessing response to immunotherapy early in a patient's course of treatment," said Enrique Sanz-Garcia, MD, Medical Oncologist and Clinician-Investigator at Princess Margaret Cancer Centre, University Health Network. "Identifying non-response earlier can support timely treatment decisions and help avoid unnecessary toxicity." The second study included banked samples from 63 patients with stage III/IV non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab (stage III) or with PD-1 inhibitors +/- chemotherapy (stage IV). Blood samples were collected pre-treatment, 2-4 weeks after treatment initiation and approximately 6-8 weeks thereafter until progression. Patients with a positive MRD test showed significantly worse PFS than those who tested negative (HR 4.8; 95% CI, 2.1-10.8; P < 0.0001). "Together, these two studies demonstrate the potential of Adela's tissue-agnostic test to predict outcomes and support clinical decision-making for patients receiving immunotherapy across a range of cancer types," said Dr. Anne-Renee Hartman, Chief Medical Officer at Adela. "Because tumor tissue is often unavailable in patients with advanced cancer, Adela's blood-only, tissue-free approach offers a universally accessible solution for this population." Adela's MRD test based on its genome-wide methylome enrichment platform is currently available to biopharmaceutical companies and other investigators for Research Use Only (RUO), including for biomarker discovery and drug development. Adela plans to commercialize the test in 2025 for use in patients who have received curative intent treatment for head & neck cancer, regardless of HPV status, to detect recurrence earlier and help guide treatment decision-making. Presentation Details Abstract #8550: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay Dr. Tuan Hoang1 Hall A, Poster Board: 30 Saturday May 31, 2025 1:30 PM-4:30 PM CDT Abstract # 2545: Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab DR. Enrique Sanz-Garcia1 Hall A, Poster Board: 192 Monday June 2, 2025 1:30 PM-4:30 PM CDT About Adela Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at 1 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada View original content to download multimedia: SOURCE Adela Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Los Angeles Times
25-05-2025
- Entertainment
- Los Angeles Times
Red sauce recipes for cooking like Nonna (or the one you wish you had)
Grandmothers are having a moment. The debut of the Netflix movie 'Nonnas' (Italian-ish for 'grandmothers') has people talking about grandmothers, and appreciating them not just for their home cooking, but for their brand of unconditional love wherein you're gazed at adoringly even after eating the entire bag of zeppole you were sent to the store to bring home. 'Nonnas,' based on the true story of a man who opens a restaurant in Staten Island to honor his mother and grandmother, captures a seemingly universal fantasy: a warm home where any potential problems are drowned out by love, laughter and a plate — or a buffet — of familiar, comforting foods: a casserole dish of lasagna; a pot of sausage and peppers; platters piled with meatballs, zucchini swimming in olive oil, and chunks of focaccia; extra tomato sauce (aka 'red sauce' or 'gravy'); a cut crystal bowl of parmesan; and platters of Italian cookies — straight from the heart and hands of the person who loves us most in the world. The promise of the nonna is not just the food. It's that love. I did not have this kind of grandmother. My grandmother Adela, on my dad's side, didn't cook — nor look at me adoringly as far as I remember. My grandmother Birdie, on my mom's side, cooked exactly one thing: oatmeal! Safe to say neither of them loved me more than anyone else in the world. For those of us who didn't grow up with the real deal, the fantasy of the forgiving nonna is still appealing. And for those who did, forget about it. My friend Toni Vartanian (né DiSanti) said she bawled through the opening scene, remembering Sundays at her grandparents' house in San Diego's Little Italy, with her parents, five uncles, all their wives, and three or four cousins from each pair. The women, she recalled, 'pulled out the pots and pans and made music and danced in the kitchen.' Sign me up! There's a popular saying that there are two kinds of people in the world: Italians, and those who wish they were Italian. After watching 'Nonnas,' I might amend the saying to: There are two kinds of Americans: Italian-Americans, and those who wish they were Italian-American. At least on Sundays. 'Nonnas' has been No. 1 on Netflix's list of 'Global Top 10 Movies' since it debuted on Mother's Day, with over 15 million viewers to date. The movie is also an homage to Italian-American cuisine, which has been having its moment now for a decade. In the 1990s, regional Italian cuisine, and Cal-Ital, eclipsed the red-sauce-heavy Italian food we grew up eating, whether it was served to us by a nonna or we experienced it at a checkered-tablecloth restaurant with wicker-covered wine-bottle candelabras. But we've returned to comforting Italian-American favorites; it was as if we all went on a collective exotic vacation only to come back with a new appreciation for the joys of home. Spaghetti and meatballs, garlic bread, lasagna, anything with ricotta cheese, and red sauce have reappeared at restaurants all over town. And the good news is, these dishes, which many might have seen as one-note, have been reimagined, using different (but not necessarily more difficult) cooking techniques and better ingredients. In 'Nonnas,' the film's star, played by Vince Vaughn, goes through the movie searching for the secret to his nonna's gravy. But all along, we know that the real secret to the sauce won't be found in a missing ingredient. The secret ingredient is his grandmother's love, and his memory of the feeling of being in the bosom of his family's home. And those of us who don't have that memory can get in the kitchen and make new memories. Whatever you decide to cook, just be sure to do as Nonna instructs and, 'Put in your heart.' Eating out this week? Sign up for Tasting Notes to get our restaurant experts' insights and off-the-cuff takes on where they're dining right now. These meatballs — recipe courtesy of the author's nonna — are made with a combination of beef and Italian sausage and simmered in tomato sauce, making for light, tender, flavorful meatballs. Put them in a sandwich, enjoy them on their own, with Butter Garlic Bread (see below) for sopping up the sauce, or serve them on top of spaghetti. There's plenty of sauce (here referred to as 'tomato gravy') in this recipe for that, the time: 3 hours. Serves 4. Thick loaves of white bread topped with a golden layer of garlicky butter is a must to soak up whatever flavors await at the table, or to act as a raft for meatballs, sausage, caponata or whatever other flavors await at the table. IMO, twice as much butter and olive oil wouldn't be too much. But (as the saying goes) I'm not a the time: 15 minutes. Serves 6 to 8. When I wrote a pasta cookbook for two women in Sicily and mentioned one morning that in America, we ate spaghetti with meatballs, they gasped! What do you mean 'with?' They asked. 'The meatballs are on top of the spaghetti?' Meatballs are a side dish in Italy, but in America, two or three of the savory, juicy balls sitting on top of a bowl of spaghetti, the whole story dressed in red sauce, is part of the American the time: 1 ½ hours. Serves 4 to 6.
Yahoo
12-04-2025
- Health
- Yahoo
Adela's Co-Founder & Chief Scientific Officer, Dr. Daniel De Carvalho, Receives 2025 Canada Gairdner Momentum Award Recognizing World-Renowned Scientists for Exceptional Scientific Research Contributions with Continued Potential for Impact on Human Health
The Canada Gairdner Awards celebrate the world's best biomedical and global health researchers FOSTER CITY, Calif., April 11, 2025 /PRNewswire/ -- Adela, Inc. is proud to announce that Daniel De Carvalho, PhD, Co-Founder and Chief Scientific Officer, has been honored with the prestigious Peter Gilgan Canada Gairdner Momentum Award recognizing his outstanding scientific contributions, including early breakthroughs in methylation and the discovery of Adela's best-in-class technology for blood-based cancer testing. Dr. De Carvalho's contributions have the potential to transform cancer screening and surveillance by enabling earlier detection of many new and recurrent cancers with a blood test, resulting in more effective treatment. The Canada Gairdner Awards recognize outstanding researchers whose unique scientific contributions have increased the understanding of human biology and disease. Since 1957, 426 awards have been bestowed on laureates from over 40 countries, and of those awardees, 102 have gone on to receive Nobel Prizes. The Gairdner Foundation is recognizing Dr. De Carvalho as a global leader in cancer epigenetics, immunotherapy, and liquid biopsy research for "the ground-breaking discovery of the role of transposable elements in regulating anti-tumour immunity through viral mimicry, which holds transformative potential for cancer therapy, and for pioneering the development of a novel blood-based test for early cancer detection, classification, and therapy monitoring." The novel approach to blood-based cancer detection, discovered by Dr. De Carvalho at University Health Network's Princess Margaret Cancer Centre, overcomes a significant challenge in the field - isolating genomic material for sequencing. Dr. De Carvalho's approach specifically isolates the information-rich (methylated) regions of the genome through a high-affinity enrichment process, allowing efficient capture of extensive, biologically-relevant genomic information. This advancement allows a single platform to be applied across many use cases in cancer, and also enables greater opportunity to detect cancer signals in the blood compared to other technologies that target a smaller set of genomic regions. Adela is developing the technology for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). "We congratulate Daniel on this tremendous honor recognizing his profound contributions to the field of cancer research," said Lisa Alderson, CEO of Adela. "Daniel's discoveries have the potential to improve the lives of the millions of people impacted by cancer each year. We are excited to take these breakthrough innovations forward with the development of Adela's genome-wide methylation platform to improve the diagnosis and management of cancer." About Adela Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at View original content to download multimedia: SOURCE Adela Sign in to access your portfolio
